<DOC>
	<DOCNO>NCT00278616</DOCNO>
	<brief_summary>Antiphospholipid syndrome disease believe due immune cell , cell normally protect body , produce protein lead abnormal clot body . This study design examine whether treat patient high dose cyclophosphamide together CAMPATH ( drug reduce function immune system ) , follow return previously collect stem cell result improvement disease . Stem cell undeveloped cell capacity grow mature blood cell , normally circulate blood stream . The purpose intense chemotherapy destroy cell immune system may cause disease . The purpose stem cell infusion produce normal immune system longer attack body . The study purpose examine whether treatment result improvement disease . The drug use study treatment drug commonly use immune suppression .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation Patients With Antiphospholipid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<criteria>1 . Age &gt; 18 year &lt; 55 year time pretransplant evaluation 2 . A 6.12.B : A ) An establish diagnosis definite primary APS Sapporo criterion follow : 1 . Positive LA and/or ACLA IgG IgM two separate measurement , AND 2 . Arterial , venous small vessel thrombosis ( confirm image doppler study histopathology , exception superficial venous thrombosis ) OR pregnancy morbidity ( define three embryonic loss , OR one premature birth due preeclampsia growth retardation , OR one fetal death ) B ) APLApositive Sneddon syndrome define association ischemic cerebrovascular event widespread livedo reticularis 3 . Patients fail treatment anticoagulation include warfarin , heparin/LMWH presence positive LA and/or ACLA IgG , IgM . Failure define described thromboembolic event ( 6.12.A2 6.12.B ) except pregnancy morbidity receive therapeutic anticoagulation . Therapeutic anticoagulation define least 5000 U regular heparin SQ BID , OR unfractionated IV heparin adjust therapeutic PTT , OR least 40 mg lovenox SQ QD ( equivalent LMWH ) , OR coumadin adjust INR least 2.0 , document within 1 month refractory event within 3 month patient know previously stable PLUS opinion investigator individual receiving adequate anticoagulation . 1 . Poor performance ( PS ) status ( ECOG &gt; 2 ) time entry , unless decline PS due disease consider reversible . 2 . Significant end organ damage ( caused APS ) : LVEF &lt; 40 % deterioration LVEF exercise test MUGA echocardiogram . Untreated lifethreatening arrhythmia . Active ischemic heart disease heart failure . DLCO &lt; 40 % FEV1/FEV &lt; 50 % . Serum creatinine &gt; 2.5 creatinine clearance &lt; 30ml/min . Liver cirrhosis , transaminases &gt; 3x normal limit bilirubin &gt; 2.0 unless due Gilbert disease . 3 . HIV positive . 4.Uncontrolled diabetes mellitus , illness opinion investigator would jeopardize ability patient tolerate aggressive treatment . 5 . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . 6 . Positive pregnancy test , inability unable pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy . 7 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . 8 . Inability give inform consent . 9 . Major hematological abnormality platelet count less 100,000/ul , ANC le 1000/ul unless due APS . 10 . Failure collect least 2.0 x 106 CD34+ / kg cell . * 11 . Patients already clinical trial APS treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>